NFTRH+; An Interesting Biotech Setup

First, a nice summary from Motley Fool for background. DVAX is the last highlight of three. A more recent piece on the company is here. My observation is that these consolidations after a big ‘FDA approval’ surge can take a long time (ref. my hold of medical robotics company TRXC). But I do like what I read of the company, still very speculative though it is.

On to the charts, which are all NFTRH+ really cares about. The first thing that caught my eye was the daily chart pattern, which has a somewhat bullish look (that’s very subjective, I grant you) as the SMA 200 rises to meet the SMA 50, at which the price currently consolidates. RSI is green and MACD is getting there. The former big up momentum is now erased per ADX black and +DI & -DI pretty much a wash as well.

A buy between the SMA 50 and SMA 200 might work well with a stop loss below the February low (15.55) or more strictly, below the January low (14.65) on a daily close.


For reference, the weekly chart shows what might already be a wedge breakout in process.


There is no upside price objective at this time other than to say that if the setup is successful it would likely go above the 2017 high.

A reminder that chart based NFTRH+ updates are technical trade setup ideas, which may not be revisited as the buy, sell, stop parameters are already noted. They are meant as a starting point for your further research if interested. I will not personally buy every item highlighted and will sometimes sell (ref. Trade Log) any item that I do buy below target (assuming I’ve not stopped out or sold for some other reason), which is something I often do as a trader. Also please be aware that I am not a fundamental stock analyst. Due diligence is your responsibility.